Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.30    0.00 (0.00%)
Bid:
1.25
Ask:
1.40
Spread: 0.15 (12.00%)
Market Cap: £21.27m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Director/PDMR Shareholding

18 Jul 2019 07:00

RNS Number : 9066F
Genedrive PLC
18 July 2019
 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

 

genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that Dr Ian Gilham, Non-Executive Chairman, acquired 51,250 ordinary shares of 1.5p each ("Ordinary Shares") in the Company at an average price of 19p per share.

 

Following these purchases, Dr Gilham is interested in 317,674 Ordinary Shares, 0.93% of the issued share capital of the Company.

 

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Ian Gilham

 

 

2.

Reason for the notification

a.

Position/status

Non-Executive Chairman

a.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

genedrive plc

b.

LEI

213800ZYODIRZ87Y4K14

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type

of instrument

Identification code

Ordinary shares of 1.5 pence each

b.

Nature of the transaction

Purchase

c.

Price(s) and volume(s)

 

Price(s)

Volume(s)

19p

51,250

 

d.

Aggregated information

· Aggregated volume

· Price

 

 

N/A

 

e.

Date of the transaction

2019-07-17; UTC time

f.

Place of the transaction

London Stock Exchange, AIM

 

For further details please contact:

genedrive plc

+44 (0)161 989 0245

David Budd: CEO

 

Matthew Fowler: CFO

 

Peel Hunt LLP

+44 (0)207 418 8900

James Steel

 

Oliver Jackson

 

 

Stanford Capital Partners Limited

 

+44 (0)20 3815 8880

 

Patrick Claridge / John Howes

 

 

 

Walbrook PR Ltd (Media Relations & Investor Relations)

 

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHEAEXXFSSNEAF
Date   Source Headline
5th Apr 201712:39 pmRNSDirector/PDMR Shareholding - Replacement
5th Apr 201711:17 amRNSDirector/PDMR Shareholding
30th Mar 20177:00 amRNSInterim Results
27th Mar 20177:00 amRNSHCV Assay submitted for CE IVD Certification
24th Mar 20177:00 amRNSNotice of Interim Results
8th Mar 20177:00 amRNSSuccessful Clinical Results - Genedrive HCV Assay
20th Feb 20177:00 amRNSDirector/PDMR Shareholding
6th Feb 20175:53 pmRNSHoldings in Company
27th Jan 20177:00 amRNSTrading Update
16th Jan 20177:00 amRNSUpdate on US Department of Defense Programme
23rd Dec 201610:48 amRNSDirector/PDMR Shareholding
30th Nov 20162:16 pmRNSResult of AGM
29th Nov 20167:00 amRNSUpdate on CFO Appointment
17th Nov 20167:00 amRNSCE-IVD Certification for Human Genotyping Test
11th Nov 20165:47 pmRNSNotice of AGM
11th Oct 20167:00 amRNSPreliminary Results for the year end 30 June 2016
21st Sep 20167:00 amRNSNotice of Preliminary Results
21st Sep 20167:00 amRNSAppointment of Chief Financial Officer
10th Aug 20167:00 amRNSGenedrive Assay used in STOP-HCV-1 Clinical Trial
2nd Aug 20167:00 amRNSTrading Update
29th Jul 20165:58 pmRNSTotal Voting Rights
25th Jul 20167:00 amRNSRe change of name, TIDM and website address
14th Jul 20163:56 pmRNSHolding(s) in Company
14th Jul 20168:19 amRNSDirector/PDMR Shareholding
14th Jul 20168:18 amRNSHolding(s) in Company
13th Jul 20162:49 pmRNSHolding(s) in Company
12th Jul 20169:05 amRNSDirector/PDMR Shareholding
11th Jul 201611:34 amRNSResult of General Meeting and Change of Name
23rd Jun 20164:54 pmRNSPosting of Shareholder Circular
23rd Jun 20167:00 amRNSProposed Placing and Amendment to GHIF Bond
7th Jun 20167:00 amRNSBusiness Update
3rd May 20167:00 amRNSSuccessful Clinical Trial of Genedrive®
18th Apr 20167:00 amRNSEpistem Begins Full Commercial Launch of Genedrive
7th Apr 20164:54 pmRNSDirector/PDMR Shareholding
31st Mar 20167:00 amRNSInterim Results
21st Mar 20167:42 amRNSFunding award from US Department of Defense
19th Feb 20167:00 amRNSUpdate on CEO Appointment
18th Feb 20167:00 amRNSAnnounces Successful Assessment of Genedrive
13th Jan 20167:00 amRNSEpistem Appoints David Budd as CEO
16th Dec 20152:18 pmRNSDirector/PDMR Shareholding
16th Dec 20152:11 pmRNSResult of AGM
26th Nov 20154:41 pmRNSHolding(s) in Company
24th Nov 20153:28 pmRNSNotice of AGM
24th Nov 20152:07 pmRNSHolding(s) in Company
28th Oct 20157:00 amRNSPreliminary Results for year ended 30 June 2015
26th Oct 20157:00 amRNSEpistem Holdings Plc - Board Change
20th Oct 20157:00 amRNSNotice of Preliminary Results
15th Oct 20157:30 amRNSDirector/PDMR Shareholding
4th Aug 20157:00 amRNSPre-Close Trading Update and Board Changes
15th Jun 201512:17 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.